10-(2-aminoethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole | 102842-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 10-(2-aminoethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole
• 英文别名: 2-(6,7,8,9-Tetrahydropyrido[1,2-a]indol-10-yl)ethanamine
• CAS: 102842-25-1
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: RDWWHJCUIKCOGE-UHFFFAOYSA-N

物化性质

• 沸点：
  401.7±30.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  31
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  丙酸酐 、 10-(2-aminoethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 生成 N-[2-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)ethyl]propanamide
  参考文献：
  名称：

  Synthesis of new tricyclic melatoninergic ligands

  摘要：

  We report the synthesis and biological evaluation of a series of new tricyclic analogs of the hormone melatonin, which act as probes of the constraints at the hormone's receptor site with regard to the lower N1-C2 region of the indole moiety of melatonin. Three of the new compounds, N-[2-(2-methoxy-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)ethyl]acetamide (9), and the respective propionamide 10 and butyramide 11, are as potent as melatonin in the Xenopus laevis melanophore model. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01125-9
• 作为产物：
  描述：

  在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 10-(2-aminoethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole
  参考文献：
  名称：

  Synthesis of new tricyclic melatoninergic ligands

  摘要：

  We report the synthesis and biological evaluation of a series of new tricyclic analogs of the hormone melatonin, which act as probes of the constraints at the hormone's receptor site with regard to the lower N1-C2 region of the indole moiety of melatonin. Three of the new compounds, N-[2-(2-methoxy-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)ethyl]acetamide (9), and the respective propionamide 10 and butyramide 11, are as potent as melatonin in the Xenopus laevis melanophore model. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01125-9

文献信息

• Substituted indolizines and derivatives as CNS agents
  申请人：Sabb Louise Annmarie

  公开号：US20060094752A1

  公开（公告）日：2006-05-04

  Compounds of formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

  提供了公式1的化合物或其药用可接受的盐：这些化合物是大脑5-羟色胺受体2C亚型的激动剂或部分激动剂。这些化合物和含有这些化合物的组合物可用于治疗多种中枢神经系统疾病，如精神分裂症。
• Pyrido[1,2-a]indoles and their use as CNS agents
  申请人：Beecham-Wuelfing GmbH & Co.

  公开号：US04968699A1

  公开（公告）日：1990-11-06

  A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; R.sub.2 and R.sub.3 are both hydrogen or together represent a bond; R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group; R.sub.6 is phenyl C.sub.1-7 alkanoyl in which the phenyl moiety is optionally substituted by one or two of halogen, nitro, meta- or para-methoxy, methyl or NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-6 alkyl or R.sub.8 and R.sub.9 together are C.sub.2-6 polymethylene, or 3,4-disubstituted by methylenedioxy or ethylenedioxy; or C.sub.1-7 alkanoyl substituted by NR.sub.10 R.sub.11 where R.sub.10 and R.sub.11 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.12 where R.sub.12 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, cyano or nitro groups; and R.sub.7 is hydrogen or C.sub.1-4 alkyl; and a pharmaceutically acceptable carrier.

  一种包含式(I)化合物或其药学上可接受的盐的制药组合物：其中：R.sub.1为氢、C.sub.1-6烷基、C.sub.1-6烷氧基或卤素；R.sub.2和R.sub.3均为氢或一起代表一个键；R.sub.4为氢，R.sub.5为氢或R.sub.4和R.sub.5一起代表一个氧基团；R.sub.6为苯基C.sub.1-7烷酰基，其中苯基部分可以选择地被卤素、硝基、间甲氧基、对甲氧基、甲基或NR.sub.8 R.sub.9取代，其中R.sub.8和R.sub.9独立地为氢或C.sub.1-6烷基，或R.sub.8和R.sub.9一起为C.sub.2-6聚亚甲基，或3,4位取代为亚甲二氧基或乙二氧基；或被NR.sub.10 R.sub.11取代的C.sub.1-7烷酰基，其中R.sub.10和R.sub.11独立地为氢或C.sub.1-4烷基，或一起为C.sub.3-7聚亚甲基，可以包含进一步的氧、硫或氮杂原子，由R.sub.12取代，其中R.sub.12为氢、C.sub.1-4烷基或苄基，并且可以选择地被一个或两个C.sub.1-4烷基、C.sub.2-5烷酰基、C.sub.1-4烷氧羰基、氨基羰基取代，氨基羰基可以选择地被一个或两个C.sub.1-6烷基或苄基取代，氰基、苯基或苄基，其中任何苯基或苄基部分可以选择地在苯环中被一个或两个卤素、CF.sub.3、C.sub.1-4烷基、C.sub.1-4烷氧基、氰基或硝基取代；R.sub.7为氢或C.sub.1-4烷基；以及药学上可接受的载体。
• Active compounds
  申请人：LES LABORATOIRES BEECHAM S.A.

  公开号：EP0167901B1

  公开（公告）日：1990-04-04
• Tetrahydropyrido(1,2-a)indole derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM - WUELFING GmbH & Co. KG

  公开号：EP0279125B1

  公开（公告）日：1992-04-29
• SUBSTITUTED INDOLIZINES AND DERIVATIVES AS CNS AGENTS
  申请人：Wyeth

  公开号：EP1807427A2

  公开（公告）日：2007-07-18